The N.N. Alexandrov National Cancer Centre is conducting a prospective observational study to evaluate the efficacy and safety of an academic CAR-T cell therapy targeting CD19 in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). This approach aims to reduce the high costs associated with commercial CAR-T therapies, potentially increasing accessibility and affordability in clinical practice. Given the rising demand for effective treatments in oncology, particularly for R/R LBCL, this study could position the center as a leader in cost-effective CAR-T therapies. The success of this trial may attract interest from pharmaceutical companies looking to collaborate or license the technology, especially if the results demonstrate superior efficacy or safety profiles compared to existing therapies.